AMPH
Amphastar Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$27.72Close
$1.3BMarket cap
$16.87 – $29.4052-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 80 · stronger than 80% of stocks over 12 months
- Tight base near its pivot pullbacks 10% → 9%; 2.3% above its $27.10 pivot
Cautions
- Trend not confirmed 6 of 8 conditions · 150-day under the 200-day, 200-day not rising
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
6%
1wk
up 10.3%
price change
1mo
up 7.4%
price change
12-month return
up 12%
market up 11% ·
its own up 4%
F-score
6 / 9
Mixed
Altman Z
2.55
Moderate risk
P/E
12.9×
price / earnings
PEG
—
P/E / EPS growth
P/B
1.6×
price / book
Earnings yield
up 8.2%
EBIT / enterprise value
Cheaper than
84%
of the market · markedly cheap
Revenue growth
down 2%
year on year
EPS growth
up 6%
latest quarter · +79 pts
Sales growth
up 5%
latest quarter · +5 pts
ROE
up 13%
return on equity
Free cash margin
up 17%
$121.2M FCF
D/E
0.79
long-term debt / equity
Net debt / EBITDA
3.2×
Interest cover
—EBIT / interest
Piotroski tests
- profitability slipped from last year
- gross margin narrowed
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- no new shares issued
Trade setup
ATR%
3.1%
$0.85 a day · 2×ATR $26.02
RS
80 / 99
vs the universe
Trend
6 / 8
150-day under the 200-day, 200-day not rising
Relative volume
1.5×
vs 50-day average
Up/down volume
1.30
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Contractions
2
10% → 9%
Pivot
$27.10
2.3% above
Volume dry-up
0.8×
10 vs 50 sessions
Trend template · 6 of 8
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 51.1% to 49.5%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 1.7% over the year, from $732.0M to $719.9M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+2% vs market2 sessions after results
Financials
- Gross 49%
- Net 14%
- Free cash 17%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $349.8M | $437.8M | $499.0M | $644.4M | $732.0M | $719.9M |
| Gross margin | 41% | 46% | 50% | 54% | 51% | 49% |
| Operating income | $11.0M | $69.9M | $107.5M | $197.0M | $205.4M | $140.4M |
| Net income | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | $98.1M |
| Net margin | 0% | 14% | 18% | 21% | 22% | 14% |
| Earnings per share | $0.03 | $1.25 | $1.74 | $2.60 | $3.06 | $2.03 |
| Free cash flow | $23.4M | $70.5M | $65.1M | $145.3M | $172.3M | $121.2M |
| Free cash margin | 7% | 16% | 13% | 23% | 24% | 17% |
| Cash | $92.6M | $126.4M | $156.1M | $144.3M | $151.6M | $170.2M |
| Long-term debt | $45.9M | $78.2M | $76.6M | $603.2M | $613.5M | $619.7M |
| Shareholders' equity | $402.3M | $445.5M | $528.7M | $639.4M | $732.3M | $788.8M |
| Shares outstanding | 47.50m | 47.71m | 48.11m | 48.07m | 47.62m | 45.65m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jul 13, 2026 | Director or officer change ↗ |
| Jul 8, 2026 | Other events ↗ |
| Jun 3, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 16, 2026 | Other events ↗ |
| Mar 6, 2026 | Director or officer change ↗ |
| Mar 6, 2026 | Material agreement ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 12, 2026 | Material agreement · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 24, 2025 | Material agreement ↗ |